A multi-center randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for Chinese patients with metastatic colorectal cancer-Reference-Cited by-同舟云学术

A multi-center randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for Chinese patients with metastatic colorectal cancer

Published:2014-12-07 Issue:1 Volume:32 Page:
ISSN:1357-0560
Container-title:Medical Oncology
language:en
Short-container-title:Med Oncol

Author:

Cao Ranhua,Zhang Shuai,Ma Dedong,Hu Likuan

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12032-014-0325-9.pdf

Reference12 articles.

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.

2. Zheng ZX, Zheng RS, Zhang SW, Chen WQ. Colorectal cancer incidence and mortality in china, 2010. Asian Pac J Cancer Prev: APJCP. 2014;15(19):8455–60.

3. Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 1998;352(9138):1413–8.

4. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22(2):229–37.

5. Roque IFM, Sola I, Martin-Richard M, Lopez JJ, Bonfill Cosp X. Second-line chemotherapy in advanced and metastatic CRC. Cochrane Database Syst Rev. 2009;15(2):CD006875. doi: 10.1002/14651858.CD006875.pub2 .

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gastrointestinal perforation associated with bevacizumab in metastatic colorectal cancer;Cancer Reports;2024-01-22

2. Cost‐effectiveness analysis of continuing bevacizumab plus chemotherapy versus chemotherapy alone after first progression of metastatic colorectal cancer;Cancer Medicine;2024-01

3. Recent Advancements in the Inhibition of Metastasis of Colorectal Cancer Using Anticancer Compounds;Handbook of Oncobiology: From Basic to Clinical Sciences;2024

4. Risks of hypertension and thromboembolism in patients receiving bevacizumab with chemotherapy for colorectal cancer: A systematic review and meta‐analysis;Cancer Medicine;2023-12

5. Different doses of bevacizumab in combination with chemotherapy for advanced colorectal cancer: a meta-analysis and Bayesian analysis;International Journal of Colorectal Disease;2023-06-08